What the investigation revealed
TIME interviewed plaintiffs across the United States who were prescribed GLP-1 drugs for diabetes or rapid weight loss.
Many described months of vomiting, inability to eat solid food, and dependence on feeding tubes even after stopping the medication.
- Complaints span gastroparesis, bowel obstruction, pancreatitis, and gallbladder removal
- Patients say they were never warned that stomach paralysis could become permanent
- Families report costly hospital stays and lost wages while recovering
Representative plaintiff stories
One Philadelphia mother said she needed multiple surgeries after Wegovy allegedly triggered intestinal blockages.
Another patient, Juanita Gantt, described losing portions of her bowel and now leads community outreach encouraging others to file.
Status of MDL 3094
All federal cases sit before Judge Gene E.K. Pratter in Philadelphia as part of MDL 3094.
Bellwether selections are expected in 2025, and lawyers are requesting fast-track discovery on Novo Nordisk and Eli Lilly marketing files.
What potential claimants should document
Attorneys interviewed by TIME stressed the value of medical records showing emergency visits, diagnostic imaging, and nutrition consults.
Patients are also encouraged to save pharmacy labels, prior authorizations, and out-of-pocket receipts that prove economic harm.
Key takeaways from the TIME report
- Manufacturers allegedly downplayed the persistence of gastroparesis symptoms
- Several plaintiffs were prescribed GLP-1 drugs off-label solely for cosmetic weight loss
- Families are pushing for clearer warnings and stronger post-marketing surveillance